To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Summary

ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.

Timeline

Start

2023-01-17

Primary completion

2029-02

Completion

2029-02

Publications

• Kim DK, Park JW, Cho HB, Choi SJ, Lee SS, Kim Y, Lee JB, Lim SM, Yu MR, Cho BC. Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC. Cancer Res Treat. 2026 Mar 31. doi: 10.4143/crt.2025.1399. Online ahead of print.

Drugs

Indications